AbbVie Inc. $ABBV Stock Position Lowered by TCTC Holdings LLC

TCTC Holdings LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 135,184 shares of the company’s stock after selling 2,730 shares during the period. AbbVie accounts for 0.9% of TCTC Holdings LLC’s investment portfolio, making the stock its 23rd biggest holding. TCTC Holdings LLC’s holdings in AbbVie were worth $31,301,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in AbbVie during the second quarter valued at $4,288,200,000. Laurel Wealth Advisors LLC boosted its position in AbbVie by 18,384.4% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after acquiring an additional 5,675,095 shares during the period. Vanguard Group Inc. grew its stake in AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of AbbVie by 169.3% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock valued at $876,662,000 after purchasing an additional 2,969,202 shares during the period. Finally, Raymond James Financial Inc. increased its holdings in shares of AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Trading Up 1.8%

Shares of NYSE:ABBV opened at $231.57 on Friday. The business’s 50 day moving average is $223.56 and its 200-day moving average is $220.85. The firm has a market capitalization of $409.28 billion, a PE ratio of 98.12, a PEG ratio of 0.81 and a beta of 0.35. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.AbbVie’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period last year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

Wall Street Analyst Weigh In

Several research firms recently commented on ABBV. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research report on Tuesday, November 4th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Finally, Evercore dropped their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $251.00.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.